Expansion of precision medicine approaches will play a key role in optimizing care and improving outcomes for breast cancer patients in 2017. Here we highlight some of the studies and FDA approvals we are most anxious to see in the coming year.
ONCOLOGY Vol 30 No 12_Suppl_2
Advertisement
Advertisement
Trending on CancerNetwork
1
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
